HOME >> BIOLOGY >> NEWS
Rising expectations from new yeast study

ever we get a wound, immune cells detect the source of chemical signals coming from the wound and migrate toward it. Chemotropism is also relevant to cancer because tumor cells metastasize in response to chemical signals released by specific tissues."

At the molecular level, the yeast mating response works through a series of steps: the signaling pheromone binds to a receptor on the cell membrane, thus activating a signaling molecule called a G-protein. G-protein is made of two parts, G-alpha and G-beta-gamma. G-beta-gamma triggers a sequence of signals along a pathway of enzymes, ending in the activation of a protein called a MAPK, which enters the cell nucleus and affects targets that block cell division.

To resume division, the cells must turn off the mating signal. Exactly how this worked was unclear until Metodiev and Stone, using a research technique called proteomics, discovered that the other part of the G-protein (G-alpha) eventually bypasses this linear signal progression and binds directly to the bottom-level MAPK. It then diverts the MAPK from the nucleus, which allows the growth signal to turn back on. This G-alpha/MAPK binding was previously unknown.

The UIC scientists also discovered that G-alpha lures the MAPK enzymes to the cell's plasma membrane where it works to help orient cell growth toward another cell's chemical signal.

"In contrast to traditional therapies, today's modern drug discovery process is directed at specific proteins and protein-protein interactions," said Metodiev. "In this case, we have demonstrated the interaction of two very important and well-characterized signaling molecules, G-alpha and MAPK. This interaction is a natural target of drug discovery research."

"It's basic scientific research but definitely has the potential to influence therapeutics," said Stone. "There are many human diseases related to problems in controlling cell growth and differentiation. For example, if we know
'"/>

Contact: Paul Francuch
francuch@uic.edu
312-996-3457
University of Illinois at Chicago
23-May-2002


Page: 1 2 3

Related biology news :

1. Rising childhood leukaemia incidence prompts conference
2. Rising ozone levels pose challenge to U.S. soybean production, scientists say
3. Rising Maryland to welcome new biotech president
4. Rising rates of overweight among preschoolers in developing countries
5. Binocular rivalry: Fulfilling visual expectations
6. Purdue yeast makes ethanol from agricultural waste more effectively
7. Carnegie Mellon U biologists identify critical player in yeast ribosome assembly
8. Protein-only prions confirmed in FSU yeast study
9. Bakers yeast rises from genome duplication
10. Building a better atlas of yeast proteins
11. New findings in yeast may reveal why growing older is the greatest carcinogen in humans

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/10/2019)... (PRWEB) , ... January 09, 2019 , ... Dr. Beanlands ... Heart Institute in Ottawa, Ontario, Canada. He is also Director of its National ... of Medicine, in the Department of Radiology, and in the Department of Cellular and ...
(Date:1/8/2019)... ... January 07, 2019 , ... Join industry experts Julie Peacock, Client Services at ... on Thursday, January 17, 2019 at 1pm EST. , This webinar will ... clinical trial process. Featured speakers will also present a case study of a leading ...
(Date:1/7/2019)... (PRWEB) , ... January 07, 2019 , ... ... (RWD) and Artificial Intelligence solutions for precision health in oncology and other key ... J.P Morgan’s exclusive meeting of investors, entrepreneurs and executives spanning the entire healthcare ...
Breaking Biology News(10 mins):
(Date:1/4/2019)... ... January 04, 2019 , ... Triangle Insights Group, a premier ... Ted will be joining the firm as a partner. , Ted has ... the pharmaceutical industry. At Triangle Insights, Ted will apply his deep expertise in ...
(Date:1/4/2019)... DIEGO (PRWEB) , ... January 03, 2019 , ... ... at the forefront of oncolytic virus-based immunotherapies for cancer, today announced the founding ... Biotherapeutics to receive critical input and guidance from key leaders in the Immuno-Oncology ...
(Date:12/19/2018)... FREDERICK, Md. (PRWEB) , ... December 19, 2018 ... ... solutions for Life Science, announces the validated release of Limfinity® version 7.1. The ... another important technical offering from RURO as 2018 comes to an end. , ...
(Date:12/18/2018)... ... 18, 2018 , ... Patients with early stages of breast cancer who undergo ... versus whole breast irradiation, a new study suggests. , Patients with early stage breast ... after removal of the cancerous tumor because there is a 30 to 40 percent ...
Breaking Biology Technology:
Cached News: